Smart molecular probes for both diagnostic and therapeutic purposes are expected to provide significant advances in clinical medicine and biomedical research. We describe such a probe that targets ␤-amyloid plaques of Alzheimer's disease and is detectable by magnetic resonance imaging (MRI) because of contrast imparted by gadolinium labeling. Three properties essential for contrast enhancement of ␤-amyloid plaques on MRI exist in this smart molecular probe, putrescine-gadolinium-amyloid-␤ peptide: (1) transport across the blood-brain barrier following intravenous injection conferred by the polyamine moiety, (2) binding to plaques with molecular specificity by putrescineamyloid-␤, and (3) magnetic resonance imaging contrast by gadolinium. MRI was performed on ex vivo tissue specimens at 7 T at a spatial resolution approximating plaque size (62.5 m 3 ), in order to prove the concept that the probe, when administered intravenously, can selectively enhance plaques. The plaque-to-background tissue contrast-to-noise ratio, which was precisely correlated with histologically stained plaques, was enhanced more than nine-fold in regions of cortex and hippocampus following intravenous administration of this probe in AD transgenic mice. Continuing engineering efforts to improve spatial resolution are underway in MRI, which may enable in vivo imaging at the resolution of individual plaques with this or similar contrast probes. This could enable early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.
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INTRODUCTION
A consensus is emerging that amyloid-␤ (A␤) peptides may play a critical role in the pathology of Alzheimer's disease (AD). The extracellular accumulation of A␤ peptides into plaques is one of the pathological hallmarks for the definitive postmortem diagnosis of AD. Currently, no method exists for directly imaging ␤-amyloid plaques in humans for a definitive premortem diagnosis of AD. Rather, indirect and nonspecific measures such as estimations of brain atrophy, metabolite concentration, or glucose metabolism are employed. A diagnostic imaging technique capable of directly visualizing one of the primary pathologies of the disease would clearly be beneficial, not only for definitive premortem diagnosis, but also for tracking the progression of the disease and monitoring the efficacy of putative therapies aimed at inhibiting the production of A␤ or reducing amyloid burden in general (Selkoe, 2000) . Radiolabeled molecular probes that bind to ␤-amyloid plaques have been demonstrated both in vitro and in mice in vivo (Wengenack et 
